VEGFA and neoplasm: On the contrary, bevacizumab serves as a monoclonal antibody against the Vascular Endothelial Growth Factor (VEGF) protein, which is a potent angiogenic factor produced by many cells to stimulate the formation of blood vessels, thus impeding tumor growth and nourishment by cutting down tumor’s supply of oxygen and nutrients.